Innovent Biologics reported that efdamrofusp alfa (IBI-302) met the primary endpoint in its phase III Star trial for neovascular age-related macular degeneration (nAMD). The Suzhou-based company said it plans to submit an NDA to China’s National Medical Products Administration. The result extends Innovent’s effort to bring competitively positioned ophthalmology biologics into regulatory review after phase II and phase III progress across retina indications. For investors and partners, an NDA submission is a concrete milestone that compresses timelines versus programs still in clinical design. The data also reinforce that China remains active in global-style late-stage pathways for eye diseases, with follow-on filings expected to define near-term commercial prospects for pipeline assets in retina.